Utilizing circulating tumour DNA as a prognostic predictor of gastric cancer: a meta-analysis

References

• Balgkouranidou, I., et al., 2013. Assessment of SOX17 DNA methylation in cell free DNA from patients with operable gastric cancer. Association with prognostic variables and survival. Clinical chemistry and laboratory medicine, 51 (7), 1505–1510.
   PubMed Web of Science ®Google Scholar
• Balgkouranidou, I., et al., 2015. Prognostic role of APC and RASSF1A promoter methylation status in cell free circulating DNA of operable gastric cancer patients. Mutation research, 778, 46–51.
   PubMed Web of Science ®Google Scholar
• Borggreve, A.S., et al., 2019. Imaging strategies in the management of gastric cancer: current role and future potential of MRI. The british journal of radiology, 92 (1097), 20181044.
   PubMed Web of Science ®Google Scholar
• Bronkhorst, A.J., Ungerer, V., and Holdenrieder, S., 2020. Early detection of cancer using circulating tumor DNA: biological, physiological and analytical considerations. Critical reviews in clinical laboratory sciences, 57 (4), 253–269.
   Web of Science ®Google Scholar
• Bu, J., et al., 2020. Enhanced detection of cell-free DNA (cfDNA) enables its use as a reliable biomarker for diagnosis and prognosis of gastric cancer. PLoS one, 15 (12), e0242145.
   PubMed Web of Science ®Google Scholar
• Cai, Z., et al., 2020. Detection of microsatellite instability from circulating tumor DNA by targeted deep sequencing. The journal of molecular diagnostics: JMD, 22 (7), 860–870.
   PubMed Web of Science ®Google Scholar
• Căinap, C., et al., 2015. Classic tumor markers in gastric cancer. Current standards and limitations. Clujul medical (1957), 88 (2), 111–115.
   PubMedGoogle Scholar
• Chae, Y.K., and Oh, M.S., 2019. Detection of minimal residual disease using ctDNA in lung cancer: current evidence and future directions. Journal of thoracic oncology, 14 (1), 16–24.
   PubMed Web of Science ®Google Scholar
• Chen, X., et al., 2020. Non-invasive early detection of cancer four years before conventional diagnosis using a blood test. Nature communications, 11 (1), 3475.
   PubMed Web of Science ®Google Scholar
• Comprehensive molecular characterization of gastric adenocarcinoma. 2014. Nature, 513 (7517), 202–209.
   PubMed Web of Science ®Google Scholar
• Costa Normando, S.R., et al., 2018. Circulating free plasma tumor DNA in patients with advanced gastric cancer receiving systemic chemotherapy. BMC clinical pathology, 18, 12.
   PubMed Web of Science ®Google Scholar
• Duval, S., and Tweedie, R., 2000. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics, 56 (2), 455–463.
   PubMed Web of Science ®Google Scholar
• Egger, M., et al., 1997. Bias in meta-analysis detected by a simple, graphical test. BMJ (clinical research ed.), 315 (7109), 629–634.
   PubMed Web of Science ®Google Scholar
• Fang, W.-L., et al., 2016. Clinical significance of circulating plasma DNA in gastric cancer. International journal of cancer, 138 (12), 2974–2983.
   PubMed Web of Science ®Google Scholar
• Fang, W.-L., et al., 2019. Analysis of the clinical significance of DNA methylation in gastric cancer based on a genome-wide high-resolution array. Clinical epigenetics, 11 (1), 154.
   Web of Science ®Google Scholar
• Faulkner, L.G., et al., 2023. The utility of ctDNA in detecting minimal residual disease following curative surgery in colorectal cancer: a systematic review and meta-analysis. British journal of cancer, 128 (2), 297–309.
   PubMed Web of Science ®Google Scholar
• Gale, D., et al., 2022. Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer. Annals of oncology, 33 (5), 500–510.
   PubMed Web of Science ®Google Scholar
• Gao, Y., et al., 2017. Diagnostic and prognostic value of circulating tumor DNA in gastric cancer: a meta-analysis. Oncotarget, 8 (4), 6330–6340.
   PubMed Web of Science ®Google Scholar
• Han, J., et al., 2014. Circulating methylated MINT2 promoter DNA is a potential poor prognostic factor in gastric cancer. Digestive diseases and sciences, 59 (6), 1160–1168.
   PubMed Web of Science ®Google Scholar
• Hariharan, R., and Jenkins, M., 2020. Utility of the methylated SEPT9 test for the early detection of colorectal cancer: a systematic review and meta-analysis of diagnostic test accuracy. BMJ open gastroenterology, 7 (1), e000355.
   PubMed Web of Science ®Google Scholar
• Hayden, J.A., et al., 2013. Assessing bias in studies of prognostic factors. Annals of internal medicine, 158 (4), 280–286.
   PubMed Web of Science ®Google Scholar
• He, C.-Z., et al., 2013. Combined use of AFP, CEA, CA125 and CAl9-9 improves the sensitivity for the diagnosis of gastric cancer. BMC gastroenterology, 13 (1), 87.
   PubMedGoogle Scholar
• Heitzer, E., Auinger, L., and Speicher, M.R., 2020. Cell-free DNA and apoptosis: how dead cells inform about the living. Trends in molecular medicine, 26 (5), 519–528.
   PubMed Web of Science ®Google Scholar
• Higgins, J.P.T., et al., 2003. Measuring inconsistency in meta-analyses. BMJ (clinical research ed.), 327 (7414), 557–560.
   PubMed Web of Science ®Google Scholar
• Hu, X.-Y., et al., 2021. Circulating methylated THBS1 DNAs as a novel marker for predicting peritoneal dissemination in gastric cancer. Journal of clinical laboratory analysis, 35 (9), e23936.
   Web of Science ®Google Scholar
• Hu, Y., et al., 2019. Predictive value of the serum RASSF10 promoter methylation status in gastric cancer. The journal of international medical research, 47 (7), 2890–2900.
   PubMed Web of Science ®Google Scholar
• Huang, Y., et al., 2020. A novel nest hybridization chain reaction based electrochemical assay for sensitive detection of circulating tumor DNA. Analytica chimica acta, 1107, 40–47.
   PubMed Web of Science ®Google Scholar
• Japanese Gastric Cancer Association. 2023. Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition). Gastric cancer, 26 (1), 1–25.
   PubMed Web of Science ®Google Scholar
• Jelski, W., et al., 2008. Alcohol dehydrogenase (ADH) isoenzymes and aldehyde dehydrogenase (ALDH) activity in the sera of patients with gastric cancer. Digestive diseases and sciences, 53 (8), 2101–2105.
   PubMed Web of Science ®Google Scholar
• Jelski, W., et al., 2010. The diagnostic value of alcohol dehydrogenase (ADH) isoenzymes and aldehyde dehydrogenase (ALDH) measurement in the sera of gastric cancer patients. Clinical and experimental medicine, 10 (4), 215–219.
   PubMed Web of Science ®Google Scholar
• Jin, Y., et al., 2020. The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors. Molecular cancer, 19 (1), 154.
   Web of Science ®Google Scholar
• Jogo, T., et al., 2021. Circulating tumor DNA analysis detects FGFR2 amplification and concurrent genomic alterations associated with FGFR inhibitor efficacy in advanced gastric cancer. Clinical cancer research, 27 (20), 5619–5627.
   PubMed Web of Science ®Google Scholar
• Karamitrousis, E.I., et al., 2021. Prognostic role of RASSF1A, SOX17 and Wif-1 promoter methylation status in cell-free DNA of advanced gastric cancer patients. Technology in cancer research & treatment, 20, 1533033820973279–1533033820973279.
   Google Scholar
• Kato, S., et al., 2018. Analysis of circulating tumor DNA and clinical correlates in patients with esophageal, gastroesophageal junction, and gastric adenocarcinoma. Clinical cancer research, 24 (24), 6248–6256.
   PubMed Web of Science ®Google Scholar
• Kim, S.S., et al., 2020. MLH1 single-nucleotide variant in circulating tumor DNA predicts overall survival of patients with hepatocellular carcinoma. Scientific reports, 10 (1), 17862.
   PubMed Web of Science ®Google Scholar
• Leal, A., et al., 2020. White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer. Nature communications, 11 (1), 525.
   Web of Science ®Google Scholar
• Leon, S., et al., 1977. Free DNA in the serum of cancer patients and the effect of therapy. Cancer research, 37 (3), 646–650.
   PubMed Web of Science ®Google Scholar
• Li, Z., and Guo, Z., 2020. Comparison of CDH1 gene hypermethylation status in blood and serum among gastric cancer patients. Pathology oncology research: POR, 26 (2), 1057–1062.
   PubMed Web of Science ®Google Scholar
• Lim, H.-K., et al., 2013. Disappearance of serum methylated p16 indicates longer survival in patients with gastric cancer. Journal of gastric cancer, 13 (3), 157–163.
   PubMedGoogle Scholar
• Lin, X., et al., 2020. Plasma cell-free DNA for screening patients with benefit-assisted neoadjuvant chemotherapy for advanced gastric cancer. ScienceAsia, 46 (4), 462–471.
   Web of Science ®Google Scholar
• Ling, Z.-Q., et al., 2013. Circulating methylated XAF1 DNA indicates poor prognosis for gastric cancer. PLoS one, 8 (6), e67195.
   PubMed Web of Science ®Google Scholar
• Maron, S.B., et al., 2019. Circulating tumor DNA sequencing analysis of gastroesophageal adenocarcinoma. Clinical cancer research, 25 (23), 7098–7112.
   PubMed Web of Science ®Google Scholar
• Moher, D., et al., 2009. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ (clinical research ed.), 339, b2535.
   PubMed Web of Science ®Google Scholar
• Oikonomidou, E., Greek General Practice Dyspepsia Group*., et al., 2011. Upper gastrointestinal endoscopy for dyspepsia: Εxploratory study of factors influencing patient compliance in Greece. BMC gastroenterology, 11 (1), 11. and,
   PubMedGoogle Scholar
• Openshaw, M.R., et al., 2020. Longitudinal monitoring of circulating tumour DNA improves prognostication and relapse detection in gastroesophageal adenocarcinoma. British journal of cancer, 123 (8), 1271–1279.
   PubMed Web of Science ®Google Scholar
• Page, M.J., et al., 2021. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ (clinical research ed.), 372, n71.
   PubMed Web of Science ®Google Scholar
• Parikh, R.B., and Prasad, V., 2016. Blood-based screening for colon cancer: A disruptive innovation or simply a disruption? JAMA, 315 (23), 2519–2520.
   PubMed Web of Science ®Google Scholar
• Peng, H., et al., 2019. CNV detection from circulating tumor DNA in late stage non-small cell lung cancer patients. Genes, 10 (11), 926.
   PubMed Web of Science ®Google Scholar
• Pessoa, L.S., Heringer, M., and Ferrer, V.P., 2020. ctDNA as a cancer biomarker: A broad overview. Critical reviews in oncology/hematology, 155, 103109.
   PubMed Web of Science ®Google Scholar
• Pimson, C., et al., 2016. Aberrant methylation of PCDH10 and RASSF1A genes in blood samples for non-invasive diagnosis and prognostic assessment of gastric cancer. PeerJ, 4, e2112.
   PubMed Web of Science ®Google Scholar
• Rawla, P., and Barsouk, A., 2019. Epidemiology of gastric cancer: global trends, risk factors and prevention. Przeglad gastroenterologiczny, 14 (1), 26–38.
   PubMed Web of Science ®Google Scholar
• Saluja, H., et al., 2018. The use of circulating tumor DNA for prognosis of gastrointestinal cancers. Frontiers in oncology, 8, 275.
   PubMed Web of Science ®Google Scholar
• Schwarzer, G., 2007. meta: An R package for meta-analysis. R news, 7 (3), 40–45.
   Google Scholar
• Sexton, R.E., et al., 2020. Gastric cancer: a comprehensive review of current and future treatment strategies. Cancer metastasis reviews, 39 (4), 1179–1203.
   PubMed Web of Science ®Google Scholar
• Smyth, E.C., et al., 2020. Gastric cancer. Lancet (London, England), 396 (10251), 635–648.
   PubMed Web of Science ®Google Scholar
• Smyth, E.C., et al., 2021. EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers. Gut, 70 (9), 1632–1641.
   PubMed Web of Science ®Google Scholar
• Song, L., et al., 2020. Opportunistic screening and survival prediction of digestive cancers by the combination of bloodmSEPT9with protein markers. Therapeutic advances in medical oncology, 12, 175883592096296.
   Web of Science ®Google Scholar
• Spolverato, G., et al., 2014. Rates and patterns of recurrence after curative intent resection for gastric cancer: a United States multi-institutional analysis. Journal of the American college of surgeons, 219 (4), 664–675.
   PubMed Web of Science ®Google Scholar
• Stroup, D.F., et al., 2000. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA, 283 (15), 2008–2012.
   PubMed Web of Science ®Google Scholar
• Thrift, A.P., and El-Serag, H.B., 2020. Burden of gastric cancer. Clinical gastroenterology and hepatology, 18 (3), 534–542.
   PubMed Web of Science ®Google Scholar
• Tierney, J.F., et al., 2007. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials, 8 (1), 16.
   PubMed Web of Science ®Google Scholar
• van Velzen, M.J.M., et al., 2022. Circulating tumor DNA predicts outcome in metastatic gastroesophageal cancer. Gastric cancer, 25 (5), 906–915.
   PubMed Web of Science ®Google Scholar
• Viechtbauer, W., 2010. Conducting meta-analyses in R with the meta for package. Journal of statistical software, 36 (3), 1–48.
   Web of Science ®Google Scholar
• Viechtbauer, W., and Cheung, M.W.-L., 2010. Outlier and influence diagnostics for meta-analysis. Research synthesis methods, 1 (2), 112–125.
   PubMed Web of Science ®Google Scholar
• Wang, G., et al., 2015. The diagnosis value of promoter methylation of UCHL1 in the serum for progression of gastric cancer. Biomed research international, 2015, 1–8.
   Web of Science ®Google Scholar
• Wang, Y., et al., 2019. Circulating tumor DNA analyses predict progressive disease and indicate trastuzumab-resistant mechanism in advanced gastric cancer. EBioMedicine, 43, 261–269.
   PubMed Web of Science ®Google Scholar
• Wong, M.C.S., et al., 2021. Global incidence and mortality of gastric cancer, 1980-2018. JAMA network open, 4 (7), e2118457.
   PubMed Web of Science ®Google Scholar
• Wu, R., et al., 2020. Detection of circulating tumor cell DNA for monitoring advanced gastric cancer. International journal of clinical and experimental pathology, 13 (2), 203–211.
   PubMed Web of Science ®Google Scholar
• Wu, Y.-C., et al., 2014. Enhanced serum methylated p16 DNAs is associated with the progression of gastric cancer. International journal of clinical and experimental pathology, 7 (4), 1553–1562.
   PubMed Web of Science ®Google Scholar
• Xi, W., et al., 2022. Molecular evolutionary process of advanced gastric cancer during sequential chemotherapy detected by circulating tumor DNA. Journal of translational medicine, 20 (1), 365.
   Web of Science ®Google Scholar
• Xu, R., et al., 2017. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nature materials, 16 (11), 1155–1161.
   PubMed Web of Science ®Google Scholar
• Xue, W.-J., et al., 2016. The value of serum RASSF10 hypermethylation as a diagnostic and prognostic tool for gastric cancer. Tumour biology, 37 (8), 11249–11257.
   PubMedGoogle Scholar
• Yan, H., et al., 2021a. Value of plasma methylated SFRP2 in prognosis of gastric cancer. Digestive diseases and sciences, 66 (11), 3854–3861.
   PubMed Web of Science ®Google Scholar
• Yan, Y., et al., 2021b. Cell-free DNA: hope and potential application in cancer. Frontiers in cell and developmental biology, 9, 639233.
   PubMedGoogle Scholar
• Yang, J., et al., 2020. Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer. Cell death & disease, 11 (5), 346.
   Web of Science ®Google Scholar
• Yi, X., et al., 2017. The feasibility of using mutation detection in ctDNA to assess tumor dynamics. International journal of cancer, 140 (12), 2642–2647.
   PubMed Web of Science ®Google Scholar
• Yoruker, E.E., et al., 2021. Fragmentation analysis of plasma DNA reveals its prognostic value in gastric cancer. The turkish journal of gastroenterology, 32 (9), 720–726.
   PubMed Web of Science ®Google Scholar
• Yu, J.-L., et al., 2014. Methylated TIMP-3 DNA in body fluids is an independent prognostic factor for gastric cancer. Archives of pathology & laboratory medicine, 138 (11), 1466–1473.
   PubMed Web of Science ®Google Scholar
• Zhang, Z., et al., 2020. Using circulating tumor DNA as a novel biomarker to screen and diagnose hepatocellular carcinoma: a systematic review and meta-analysis. Cancer medicine, 9 (4), 1349–1364.
   PubMed Web of Science ®Google Scholar